506 filings
Page 2 of 26
DEF 14A
NERV
Minerva Neurosciences Inc
Definitive proxy
15 Aug 23
9:25am
EFFECT
NERV
Minerva Neurosciences Inc
10 Aug 23
Notice of effectiveness
12:15am
424B3
NERV
Minerva Neurosciences Inc
9 Aug 23
Prospectus supplement
5:12pm
UPLOAD
NERV
Minerva Neurosciences Inc
7 Aug 23
Letter from SEC
12:00am
CORRESP
NERV
Minerva Neurosciences Inc
7 Aug 23
Correspondence with SEC
12:00am
S-3
NERV
Minerva Neurosciences Inc
Shelf registration
4 Aug 23
8:07am
10-Q
2023 Q2
NERV
Minerva Neurosciences Inc
Quarterly report
1 Aug 23
7:01am
SC 13D
NERV
Minerva Neurosciences Inc
7 Jul 23
Minerva Neurosciences / Boehringer ownership change
4:18pm
3
AG Boehringer
7 Jul 23
Minerva Neurosciences / AG Boehringer ownership change
4:15pm
D
NERV
Minerva Neurosciences Inc
3 Jul 23
$20.00 mm in equity / options / securities to be acquired, 4 investors
4:04pm
8-K
NERV
Minerva Neurosciences Inc
28 Jun 23
Minerva Neurosciences Announces $20 Million in Private Placement Priced at a Premium to Market
8:37am
8-K
NERV
Minerva Neurosciences Inc
20 Jun 23
Other Events
8:41am
8-K
NERV
Minerva Neurosciences Inc
2 Jun 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:05pm
10-Q
2023 Q1
NERV
Minerva Neurosciences Inc
Quarterly report
15 May 23
7:01am
8-K
NERV
Minerva Neurosciences Inc
5 May 23
Departure of Directors or Certain Officers
4:18pm
4
Remy Luthringer
2 May 23
Minerva Neurosciences / Remy Luthringer ownership change
6:15pm
4
Geoff Race
2 May 23
Minerva Neurosciences / Geoff Race ownership change
6:14pm
4
NERV
Minerva Neurosciences Inc
2 May 23
Minerva Neurosciences / Frederick W Ahlholm ownership change
6:13pm
8-K
NERV
Minerva Neurosciences Inc
1 May 23
Minerva Neurosciences Announces the NDA Filing for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
7:18am
10-K/A
2022 FY
NERV
Minerva Neurosciences Inc
20 Apr 23
Annual report (amended)
4:58pm